What You Should Know:

您应该知道：

– Nucs AI, a company that uses AI in precision medicine for the diagnosis and treatment of prostate cancer, today announces that it has closed a $3.5 million seed round of funding.

–在精准医学中使用人工智能诊断和治疗前列腺癌的Nucs AI公司今天宣布，它已经完成了一轮350万美元的种子资金。

– The company will use the funding to further build out its platform and to support FDA clearance for its technology in the United States.

。

Nucs AI: Transforming Prostate Cancer Diagnosis and Treatment with Precision Medicine

Nucs AI：用精准医学改变前列腺癌的诊断和治疗

Founded in 2023, Nucs AI is pioneering advancements in prostate cancer care through the integration of precision medicine and artificial intelligence (AI). With global prostate cancer cases projected to double between 2020 and 2040, the company aims to revolutionize patient outcomes by optimizing the use of prostate-specific membrane antigen (PSMA)-targeted imaging and therapeutics..

Nucs AI成立于2023年，通过精准医学和人工智能（AI）的整合，在前列腺癌护理方面取得了开创性进展。预计2020年至2040年间全球前列腺癌病例将翻一番，该公司旨在通过优化前列腺特异性膜抗原（PSMA）靶向成像和治疗的使用，彻底改变患者的预后。。

Nucs AI offers two AI-powered tools designed to enhance clinical decision-making:

Nucs AI提供了两种人工智能工具，旨在增强临床决策能力：

DeepPSMA: Employs discriminative AI for rapid, accurate detection, staging, and quantification of prostate cancer using PSMA-PET/CT imaging.SelectPSMA: Predicts individual patient response to PSMA-targeted radiopharmaceuticals, aiding in personalized cancer treatment strategies.

DeepPSMA：使用PSMA-PET/CT成像，使用判别性AI快速，准确地检测，分期和定量前列腺癌。SelectPSMA：预测个体患者对PSMA靶向放射性药物的反应，有助于个性化的癌症治疗策略。

PSMA-PET/CT imaging has become the gold standard for detecting and staging prostate cancer, offering superior accuracy compared to conventional imaging. Complementing this, PSMA-targeted radiopharmaceuticals, such as 177Lu-PSMA-617 (Pluvicto), deliver internal radiation therapy directly to prostate cancer cells, slowing or reducing tumor growth..

PSMA-PET/CT成像已成为检测和分期前列腺癌的金标准，与常规成像相比具有更高的准确性。作为补充，靶向PSMA的放射性药物，如177Lu-PSMA-617（Pluvicto），直接向前列腺癌细胞提供内部放射治疗，减缓或减少肿瘤生长。。

The American Cancer Society reports that prostate cancer is the most commonly diagnosed cancer among men, with 1.5 million global cases annually and 299,000 new cases expected in the U.S. in 2024 alone. This underscores the urgent need for innovative tools to improve care delivery and outcomes.

美国癌症协会（American Cancer Society）报告称，前列腺癌是男性中最常被诊断出的癌症，全球每年有150万例前列腺癌病例，仅2024年美国就预计有299000例新病例。这强调了迫切需要创新工具来改善护理服务和结果。

Nucs AI’s mission is to equip clinicians with state-of-the-art resources to streamline workflows, enhance hospital capacity, and elevate patient care standards. As highlighted by Co-Founder and CEO Nijat Ahmadov, Nucs AI focuses on enabling personalized cancer care by identifying patients most likely to benefit from advanced PSMA-targeted therapies through its proprietary SelectPSMA technology..

Nucs AI的使命是为临床医生配备最先进的资源，以简化工作流程，提高医院能力，并提高患者护理标准。正如联合创始人兼首席执行官Nijat Ahmadov所强调的那样，Nucs AI专注于通过其专有的SelectPSMA技术识别最有可能从先进的PSMA靶向治疗中受益的患者，从而实现个性化癌症护理。。

By integrating AI with precision medicine, Nucs AI is setting new benchmarks in the diagnosis and treatment of prostate cancer, ensuring that patients receive tailored care for optimal clinical benefit.

通过将人工智能与精准医学相结合，Nucs AI正在为前列腺癌的诊断和治疗设定新的基准，确保患者获得量身定制的护理，以获得最佳的临床益处。